Oxford Nanopore prevails for fourth time in patent hearing

Oxford Nanopore has prevailed once again following the decision yesterday by the European Patent Office (EPO) to revoke a second PacBio European Patent, EP3170904. This decision is consistent with that of an earlier EPO decision revoking PacBio European Patent EP3045542, as well as rulings from the ITC and US Court of Appeal that the claims of the respective patents were not entitled to a broad interpretation of the term ‘single molecule sequencing’.